Olafertinib (RX-518) is an oral, irreversible, and mutant-selective EGFR inhibitor designed to target T790M-mediated resistance in non-small cell lung cancer (NSCLC). It demonstrates potent activity in both cellular assays and in vivo xenograft models, supporting its investigation as a therapeutic agent for EGFR-mutant NSCLC.